BCAL speeds national rollout of Avantect cancer blood tests

BCAL Diagnostics Limited ( (AU:BDX) ) has provided an update.

BCAL Diagnostics has expanded national access to its Avantect pancreatic and ovarian early detection blood tests via selected Sonic Healthcare pathology centres in New South Wales, Victoria and Queensland, and through a new agreement with Healius Pathology Network. The move builds on the January launch at Sydney Breast Clinic and strengthens BCAL’s collaboration with Sonic Healthcare, broadening clinical uptake of its blood-based cancer diagnostics portfolio, including BREASTESTplus, for patients at elevated risk.

Avantect uses cell-free DNA analysis, incorporating genomic and epigenomic data with machine learning, to support earlier detection of pancreatic and ovarian cancers in higher-risk patients. National rollout through major pathology providers positions BCAL to accelerate commercialisation, deepen its presence in the cancer diagnostics market and improve access to advanced screening tools that may enhance treatment options through earlier diagnosis.

The most recent analyst rating on (AU:BDX) stock is a Sell with a A$0.09 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.

More about BCAL Diagnostics Limited

BCAL Diagnostics Limited is an Australian healthcare company focused on early cancer detection through non-invasive blood-based diagnostics. Its lead product, BREASTESTplus, is a rule-out blood test used alongside mammography to improve screening and diagnostic outcomes in women with dense breast tissue, and it holds exclusive rights to distribute Avantect cancer tests in Australia and New Zealand.

Average Trading Volume: 291,057

Technical Sentiment Signal: Sell

Current Market Cap: A$33.55M

See more insights into BDX stock on TipRanks’ Stock Analysis page.